Circulating tumour DNA (ctDNA) to guide adjuvant chemotherapy and surveillance strategies in patients with stage II colon cancer

本研究试图证明基于ctDNA结果的辅助治疗策略将减少II期结肠癌患者接受辅助化疗的数量，同时不影响无复发生存。前瞻性多中心研究纳入450例II期结肠癌患者。患者将根据ctDNA结果（A组，n = 300）或标准临床标准（B组，n = 150）按2:1随机分组接受治疗。

This study is attempting to demonstrate that an adjuvant therapy strategy based on ctDNA results will reduce the number of patients with stage II colon cancer receiving adjuvant chemotherapy without compromising recurrence free survival. Prospective multi-centre study enrolling 450 stage II colon cancer patients. Patients will be randomized 2:1 to be treated according to ctDNA results (Arm A, n = 300), or per standard clinical criteria (Arm B, n = 150).